

1. **Investment Rationale**

Gamida Cell is pioneering a diverse immunotherapy pipeline of curative cell therapies for patients with cancers and serious blood diseases. Applying a proprietary NAM expansion platform for umbilical cord blood and allogeneic NK cells to create therapies with the potential to redefine standards of care. Successfully completed phase 3 clinical trial, planning to initiate rolling BLA submission in H1, 2022.

2. **Business Strategy**

Our ability to generate future revenue from product sales will depend heavily on our ability to ensure procedures utilizing our product candidates are approved for coverage and adequate reimbursement from governmental agencies, private insurance plans, managed care organizations, and other third-party payers in jurisdictions where they have been approved for marketing. In addition, we are looking for a strategic partner.

3. **Core Technology**

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant solution for patients with blood cancers. Omidubicel is the first bone marrow transplant graft to receive Breakthrough Therapy Designation and Orphan Drug from the U.S. FDA. Gamida also develops a genetic engineered NK cell platform for the treatment of hematologic and solid tumors.

4. **Product Profile/Pipeline**

A Leading Genetically Engineered NK Cell pipeline programs including GDA-301, GDA-401, GDA-501 and GDA-601, which utilize CAR- and CRISPR-mediated strategies to increase targeting, potency and persistence against hematologic malignancies and solid-tumors. GDA-201, the lead candidate in the NAM-enabled NK pipeline, that has demonstrated promising clinical data in a fresh formulation is being developed as a cryopreserved off the shelf formulation.

5. **What's Next?**

Gamida is developing a wholly owned pipeline of advanced cell therapies with the potential to redefine standards of care across a range of diseases. The financials plans are (1) Omidubicel – Initiating rolling BLA submission for omidubicel in 1H2022 (2) Evaluating strategic alternatives for omidubicel (3) Ready to advance GDA-201 (4) Advancing genetically modified NK cell immunotherapy programs.

